In this issue of Neuron, Neuner et al. (2019) report the generation of Alzheimer's disease (AD) transgenic mouse models on a panel of 28 background strains, showing marked background-dependent phenotypic variability. These findings imply that analogous variation in human AD phenotypes may be due, at least in part, to subtle effects of genetic background.
In this issue of Neuron, Neuner et al. (2019) report the generation of Alzheimer's disease (AD) transgenic mouse models on a panel of 28 background strains, showing marked background-dependent phenotypic variability. These findings imply that analogous variation in human AD phenotypes may be due, at least in part, to subtle effects of genetic background.
Despite the fact that mutations in amyloid-related genes like APP and PSEN1 cause an autosomal dominant form of the full spectrum of Alzheimer's disease (AD) clinical and neuropathological phenotypes, transgenic mice that overexpress these same genes develop a limited phenotype focused primarily on amyloid deposition and, to a lesser extent, neuroinflammation, without robust behavioral, neuronal loss of neurofibrillary tangle phenotypes. Thus, although transgenic mice are the ''work horse'' of translational studies in AD, it is clear that they do not completely recapitulate the phenotype of human AD; it is speculated that failure of clinical trials based on preclinical work in transgenic mice is one consequence of this discrepancy. The manuscript by Neuner et al. (2019) in this issue of Neuron examines the hypothesis that part of the issue with examining phenotype in transgenic mice is the use of mice representing a single inbred strain, which does not model the potential impact of genetic heterogeneity on disease expression. To test this hypothesis, they examine the effects on behavioral and neuropathological phenotypes of changing the genetic background of the well-characterized 5X FAD model of AD (Oakley et al., 2006 ). This transgenic model overexpresses two transgenes: human APP, which contains three different mutations that are each associated with early-onset (EO) AD, and a PSEN1 transgene that harbors two different mutations, each associated with EO AD. Both the APP mutations and the PSEN1 mutations are known to impact APP processing, leading to enhanced deposition of Ab. In humans, any one of these gene mutations leads to a fully penetrant autosomal dominant disease associated with EO dementia (usually under 50). It should be noted, of course, that multiple other genes clearly influence risk for AD in patients, including prominently APOE and many genes implicated in neuroinflammation, e.g., TREM2 and CD33.
Multiple transgenic models have been established with one or two of these mutations that develop plaques in adulthood, neuroinflammation, but variable degrees of cognitive change, and, in general, no detectable neuronal loss or neurofibrillary tangle phenotype. In contrast, amyloid deposition does induce tangle formation in 3D human stem cell-derived neural cultures expressing EO-FAD mutations (Choi et al., 2014) . In 5X FAD mice, the combination of five different genetic mutations, along with overexpression of the two disease-causing genes, leads to a dramatic and fairly rapid phenotype of Ab deposition at early age, neuroinflammatory phenotypes, and a less robust change in behavior. Neuner et al. (2019) show that different murine genetic backgrounds impact phenotype of the 5X FAD mice, and demonstrate clear and important differences in amyloid deposition and in behavioral consequences based on background strain. They introduce an intriguing panel of F1 hybrids that potentially allow dissection of these traits to evaluate gene and gene X environment factors that influence disease heterogeneity.
There are three important take-home points. The first, understood for years, but not systematically investigated in this depth, is that mouse strain can have a dramatic impact on phenotype, espe-cially performance on cognitive tests, and this can have a profound effect in transgenic mice. The authors argue that this issue of background strain highlights the effects of subtle genetic differences and helps explain why phenotypes of different transgenic mice might differ from one another and, of course, from humans. Of note, in their hands the commonly used C57BL/6J strain is relatively resilient to pathological changes. Second, they suggest that subtle differences in specific genes or sets of genes can, individually or collectively, deeply impact phenotype. These observations lead to new ways to think about the consequences of genetic risk factors in humans, for testing and understanding complex issues of heterogeneity of disease phenotypes, and potentially to use cross-species comparisons to discover additional risk factors that impact disease phenotypes. Finally, this last point deserves special attention-might deeper insight into human genetics come from mouse genotype-phenotype studies?
These results are intriguing on many levels. In addition to a detailed description of how subtle genetic alterations impact phenotype in an AD model, the data also suggest plausible reasons to explain the well-documented observations that phenotypes ''drift'' over rounds of breeding, and how different, seemingly similar mice might have different phenotypes if generated on different strains. More importantly, the generation of well-characterized F1 animals and the robustness of the strain-phenotype correlations suggest fertile ground for gene finding, and for additional ways to look at heterogeneity including strain-environment interactions. It also provides caution when interpreting the results of crosses of transgenics with knockouts or other lines of transgenic mice, as the F1s might well inherit different alleles from the parental crosses that could impact phenotype. The current studies focused on the two primary phenotypes observed in 5X FAD mice-cognition and amyloid depositsbut the availability of these datasets and these mice is likely to lead to multiple follow-up experiments looking at other features of AD-including tau-related alterations, synaptic or neuronal loss, and neuroinflammation, with insights sure to follow.
The relationship between mouse genotype-phenotype correlations and the genetics of human disease bears further comment. Over the past decade, roughly three dozen genes have been validated to influence risk for AD across genomewide association studies (GWASs) (Jansen et al., 2019). Commonly used AD mouse models have been developed on heterogeneous genetic backgrounds, which could arguably carry effects on pathological phenotypes such as Ab deposition and cognitive deficits. Based on analyses of a subset of known AD risk genes in over two dozen genetically diverse F1 mouse strains, with and without FAD mutations, a substitution (E163D) in mouse ApoE, an ortholog of the most prevalent human AD risk gene, was found to affect a single aspect of behavior (contextual fear acquisition), specifically in females. However, this mouse-specific Apoe mutation does not exist in the human APOE allele, making a comparison on risk for AD in humans not readily feasible.
Assessment of a subset (total of 21) of other AD gene candidates based on GWAS revealed no significant associations with any single gene. However, the genes were collectively found to generate a genetic risk score differentiating contextual fear acquisition in ''impaired'' versus ''unimpaired'' strains. Meanwhile, no associations were observed for other behavioral measures of key pathologies, such as amyloid burden. Thus, at this point, no unique variants in mouse orthologs of human AD GWAS genes were associated with AD phenotype across the mouse strains, except for one variant in Apoe, which is not relevant in the human APOE gene.
In an assessment of gene expression differences in 60 genes shown to be differentially expressed in AD, 39 revealed changes that were concordant between mouse and human. Interestingly, the most significant expression differences were observed for the AD-associated innate immune genes, Cd33, Trem2, Bin1, and Clu. While replication of these findings is still needed, these data suggest that one of the major contributors to pathological phenotype across genetically diverse AD mouse strains is innate immune response. The vast majority of novel human AD genes are associated with innate immunity, specifically contributing to microglial-induced neuroinflammation. Interestingly, in studies of resilience to AD in humans, the presence or absence of glial activation and neuroinflammation has been shown to be a major differentiating factor (Perez-Nievas et al., 2013) . Perhaps this will be shown in follow-up studies to be a major factor contributing to resilience to cognitive impairment in AD mouse strains as well.
The current studies, along with recent efforts such as Model AD (https://modelad.org/), suggest that additional models, taking into account genetic heterogeneity, using outbred background strains, ''humanizing'' as many genes as possible, or using only ''knockin'' approaches, deserve important consideration. Certainly, improved modeling of phenotypes in mice could be argued to be critical in mapping the model to the human disease it is intended to represent. It may be that complexity of genetic background is part and parcel of the human condition, and taking advantage of the ability to reproduce that in mice will allow improved models and new insights.
